Our publications

1.
Robson AG, Egan C, Holder GE, Bird AC, Fitzke FW. Comparing rod and cone function with fundus autofluorescence images in retinitis pigmentosa. Adv Exp Med Biol. 2003;533:41–7.
1.
Robson AG, El-Amir A, Bailey C, Egan CA, Fitzke FW, Webster AR, et al. Pattern ERG correlates of abnormal fundus autofluorescence in patients with retinitis pigmentosa and normal visual acuity. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3544–50.
1.
Dandekar SS, Ebenezer ND, Grayson C, Chapple JP, Egan CA, Holder GE, et al. An atypical phenotype of macular and peripapillary retinal atrophy caused by a mutation in the RP2 gene. Br J Ophthalmol. 2004 Apr;88(4):528–32.
1.
Robson AG, Egan CA, Luong VA, Bird AC, Holder GE, Fitzke FW. Comparison of fundus autofluorescence with photopic and scotopic fine-matrix mapping in patients with retinitis pigmentosa and normal visual acuity. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4119–25.
1.
McBain VA, Egan CA, Pieris SJ, Supramaniam G, Webster AR, Bird AC, et al. Functional observations in vitamin A deficiency: diagnosis and time course of recovery. Eye (Lond). 2007 Mar;21(3):367–76.
1.
Sivaprasad S, Kung BT, Robson AG, Black G, Webster AR, Bird A, et al. A new phenotype of macular dystrophy associated with a mitochondrial A3243G mutation. Clin Exp Ophthalmol. 2008 Feb;36(1):92–3.
1.
Schmitz-Valckenberg S, Fan K, Nugent A, Rubin GS, Peto T, Tufail A, et al. Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. Arch Ophthalmol. 2008 Mar;126(3):330–5.
1.
Sivaprasad S, Webster AR, Egan CA, Bird AC, Tufail A. Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am J Ophthalmol. 2008 Aug;146(2):228–34.
1.
Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, et al. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4340–6.
1.
Patel PJ, Bunce C, Tufail A. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared to standard therapy in  subjects with choroidal neovascularisation secondary to age-related macular  degeneration: clinical trial design. Trials. 2008 Oct 14;9:56.
1.
Povazay B, Hofer B, Torti C, Hermann B, Tumlinson AR, Esmaeelpour M, et al. Impact of enhanced resolution, speed and penetration on three-dimensional retinal optical coherence tomography. Opt Express. 2009 Mar 2;17(5):4134–50.
1.
Chen FK, Patel PJ, Xing W, Bunce C, Egan C, Tufail AT, et al. Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3464–72.
1.
Schmitz-Valckenberg S, Ong EEL, Rubin GS, Peto T, Tufail A, Egan CA, et al. Structural and functional changes over time in MacTel patients. Retina. 2009 Oct;29(9):1314–20.
1.
Michaelides M, Kaines a, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study). 12-Month Data: Report 23802. Ophthalmology [Internet]. 2010;117:1078–86.
1.
Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, et al. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol. 2010 Feb;17(1):66–73.
1.
Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy  in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010 May;30(5):781–6.
1.
Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3.
1.
Tufail A, Patel PJ, Egan C, Hykin P, Cruz L da, Gregor Z, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ [Internet]. 2010 Jun 10 [cited 2020 Oct 19];340(jun09 4):c2459.
1.
Mackenzie S, Schmermer C, Charnley A, Sim D, Tah V, Dumskyj M, et al. SDOCT imaging to identify macular pathology in patients diagnosed with diabetic maculopathy by a digital photographic retinal screening programme. PLoS One. 2011 May 6;6(5):e14811.
1.
Patel PJ, Chen FK, Da Cruz L, Rubin GS, Tufail A. Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 May 11;52(6):3089–93.
1.
Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011 Dec;118(12):2453–60.
1.
Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of ophthalmology [Internet]. 2012;130:972–9.
1.
Braithwaite T, Vugler A, Tufail A. Autoimmune retinopathy. Ophthalmologica. 2012;228(3):131–42.
1.
Dunbar HMP, Crossland MD, Bunce C, Egan C, Rubin GS. The effect of low vision rehabilitation in diabetic eye disease: a randomised controlled trial protocol. Ophthalmic Physiol Opt. 2012 Jul;32(4):282–93.
1.
Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012 Sep;57(5):389–414.
1.
Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UEK, Clemons TE, Gillies MC, et al. “En face” OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6145–52.
1.
Degli Esposti S, Egan C, Bunce C, Moreland JD, Bird AC, Robson AG. Macular pigment parameters in patients with macular telangiectasia (MacTel) and normal subjects: implications of a novel analysis. Invest Ophthalmol Vis Sci. 2012 Sep 25;53(10):6568–75.
1.
Simó R, Hernández C. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol. 2012 Oct;96(10):1285–90.
1.
Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UEK, Clemons TE, Gillies MC, et al. The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012 Nov 29;53(12):7889–95.
1.
Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: The 12-month results from the repair study. Ophthalmology. 2013;120(9):1944–6.
1.
Hernández C, Simó R. Somatostatin replacement: a new strategy for treating diabetic retinopathy. Curr Med Chem. 2013;20(26):3251–7.
1.
Sim DA, Keane PA, Zarranz-Ventura J, Fung S, Powner MB, Platteau E, et al. The effects of macular ischemia on visual acuity in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2353–60.
1.
Sim DA, Keane PA, Mehta H, Fung S, Zarranz-Ventura J, Fruttiger M, et al. Repeatability and reproducibility of choroidal vessel layer measurements in diabetic retinopathy using enhanced depth optical coherence tomography. Invest Ophthalmol Vis Sci. 2013 Apr 23;54(4):2893–901.
1.
Niskopoulou M, Balaskas K, Leung I, Sallo FB, Clemons TE, Bird AC, et al. Is indocyanine green angiography useful for the diagnosis of macular telangiectasia type 2? Br J Ophthalmol. 2013 Jul;97(7):946–8.
1.
Fujinami K, Sergouniotis PI, Davidson AE, Wright G, Chana RK, Tsunoda K, et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. Am J Ophthalmol. 2013 Sep;156(3):487-501.e1.
1.
Sim DA, Keane PA, Zarranz-Ventura J, Bunce CV, Fruttiger M, Patel PJ, et al. Predictive factors for the progression of diabetic macular ischemia. Am J Ophthalmol. 2013 Oct;156(4):684–92.
1.
Simó R, Hernández C. Neurodegeneration in the diabetic eye: New insights and therapeutic perspectives. Trends in Endocrinology and Metabolism. 2014;25:23–33.
1.
Tufail A. The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: Report 1: Visual acuity manuscript no. 2013-568. Ophthalmology. 2014;121(5):1092–101.
1.
Sim DA, Keane PA, Fung S, Karampelas M, Sadda SR, Fruttiger M, et al. Quantitative analysis of diabetic macular ischemia using optical coherence tomography. Invest Ophthalmol Vis Sci. 2014 Jan 21;55(1):417–23.
1.
Errera MH, Michaelides M, Keane PA, Restori M, Paques M, Moore AT, et al. The extended clinical phenotype of dome-shaped macula. Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):499–508.
1.
Mukherjee R, Robson AG, Holder GE, Stockman A, Egan CA, Moore AT, et al. A detailed phenotypic description of autosomal dominant cone dystrophy due to a de novo mutation in the GUCY2D gene. Eye (Lond). 2014 Apr;28(4):481–7.
1.
Braithwaite T, Holder GE, Lee RWJ, Plant GT, Tufail A. Diagnostic features of the autoimmune retinopathies. Autoimmun Rev. 2014 May;13(4–5):534–8.
1.
Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol. 2014 May;157(5):960–70.
1.
Butt T, Patel PJ, Tufail A, Rubin GS. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity. Appl Health Econ Health Policy. 2014 Jun;12(3):289–97.
1.
Sim DA, Keane PA, Rajendram R, Karampelas M, Selvam S, Powner MB, et al. Patterns of peripheral retinal and central macula ischemia in diabetic retinopathy as evaluated by ultra-widefield fluorescein angiography. Am J Ophthalmol. 2014 Jul;158(1):144-153.e1.
1.
Naing A, Kenchaiah M, Krishnan B, Mir F, Charnley A, Egan C, et al. Maternally inherited diabetes and deafness (MIDD): diagnosis and management. J Diabetes Complications. 2014 Aug;28(4):542–6.
1.
Symes RJ, Liew G, Tufail A. Sight-threatening diabetic eye disease: an update and review of the literature. Br J Gen Pract. 2014 Oct;64(627):e678-680.
1.
Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014 Oct;121(10):1966–75.
1.
De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2014 Dec;158(6):1228-1238.e1.
1.
Keane PA, de Salvo G, Sim DA, Goverdhan S, Agrawal R, Tufail A. Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. Clin Ophthalmol. 2015;9:353–66.